![A coiling protein 'shell,' called a nucleocapsid, shown here, surrounds Ebola's genetic material, which consists of single-strand RNA. University of Delaware researchers are simulating the way molecules of this nucleocapsid move and interact, atom by atom, to understand their functions and expose targets for anti-viral treatments [Credit: Juan Perilla Laboratory].](https://www.drugtargetreview.com/wp-content/uploads/Ebola-nucleocapsid-e1603365997854.jpg)
news
The nucleocapsid as a novel drug target for Ebola virus
Using supercomputer stimulations researchers reveal that the structural stability of the Ebola nucleocapsid is depended on the presence of RNA and interactions with charged ions.
List view / Grid view
Covid-19
news
Severe COVID-19 symptoms may not be caused by cytokine storm
An analysis reveals that in comparison to other inflammatory diseases such as cytokine-release syndrome (CRS) and sepsis, the levels of cytokines in severely ill COVID-19 patients is low.
news
SARS-CoV-2 also uses neuropilin-1 to infect human cells
Researchers reveal that SARS-CoV-2 is more infectious than SARS-CoV because it can use both ACE2 and neuropilin-1 to infect cells.
news
CBD could treat inflammation caused by COVID-19, study shows
Researchers have found that CBD reduces inflammation in the lungs of COVID-19 mouse models by increasing levels of the apelin peptide.
news
First draft sequence of human proteome released
Researchers have mapped 90 percent of the human proteome, which could inform the development of new medicines.
news
SARS-CoV-2 papain-like protease could be a novel drug target
Scientists suggest targeting the SARS-CoV-2 papain-like protease (PLpro) with inhibitors could prevent the spread of infection.
news
Targeting host proteins could lead to pan-coronavirus antivirals
Researchers suggest that targeting host proteins with drugs, rather than directly targeting enzymes or proteins on SARS-CoV-2 and related coronaviruses, could improve outcomes.
news
Study reveals roles of antibodies in SARS-CoV-2 disease severity
Researchers have found that the level of antibodies in the serum of SARS-CoV-2 patients correlated with disease severity.
news
Over 200 molecules and genes linked to COVID-19 severity
A team has identified 219 molecules and genes that influence the severity of COVID-19 in patients, providing information that could aid the development of therapeutics.
news
Researchers uncover drivers of memory B cell formation
The team demonstrated that expression of Bach2 protein and reduced mTORC1 activity is necessary for germinal B cells to become memory B cells.
news
COVID-19 vaccines should not be affected by SARS-CoV-2 mutations, researchers say
A common SARS-CoV-2 mutation known as D614G should not impact on the efficacy of COVID-19 vaccines, a study has shown.
news
High doses of favipiravir combat SARS-CoV-2 in hamsters
A team showed that high doses of favipiravir can treat hamsters infected with SARS-CoV-2, whereas hydroxychloroquine has no effect.
news
Researchers suggest blocking factor D protein could combat SARS-CoV-2
A team has said that inhibiting the factor D protein could prevent SARS-CoV-2 from turning the immune system against healthy cells.
news
SARS-CoV-2-targeting antibodies persist for at least three months in COVID-19 patients
Two separate studies show that IgG serotype antibodies targeting the SARS-CoV-2 spike protein are still detectable in patient’s blood and saliva after 90 days.
news
SARS-CoV-2 mechanism of infection revealed using cryo-electron microscopy
Researchers have found that the surface of SARS-CoV-2 can take on at least 10 different structural states when in contact with ACE2.
